Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042668 | 0.87 | TSHR (0.44) | TSHRALDH1A1 | |
| SCHEMBL6435661 | 0.85 | TSHR (0.48) | TSHRALDH1A1 | |
| SCHEMBL15053528 | 0.77 | TSHR (0.48) | TSHRALDH1A1 | |
| SCHEMBL45114 | 0.77 | TSHR (0.48) | TSHRALDH1A1 | |
| SCHEMBL192059 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL318154 | 0.74 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL4534104 | 0.72 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL3027388 | 0.72 | TSHR (0.39) | TSHRALDH1A1 | |
| SCHEMBL6006373 | 0.71 | TSHR (0.41) | TSHRALDH1A1 | |
| SCHEMBL15900023 | 0.70 | DNM1 (0.42) | TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0533244-B1 | Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists | MERCK & CO INC (US) | 1997-12-17 | — | — | EP | claimed |
| JP-7149825-A | — | — | None | — | — | JP | disclosed |
| US-20240209190-A1 | CONJUGATED DIENE-BASED POLYMER, RUBBER COMPOSITION, RUBBER-CROSSLINKED SUBSTANCE, AND TIRE | ZS ELASTOMERS CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4373493-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITY | Nurix Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4370123-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH DIMINISHED IMID ACTIVITY | Nurix Therapeutics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| WO-2024086296-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | MEKANISTIC THERAPEUTICS LLC (US) | 2024-04-25 | — | — | WO | disclosed |
| EP-3604365-B1 | CONJUGATED DIENE POLYMER AND METHOD FOR PRODUCING CONJUGATED DIENE POLYMER | SUMITOMO CHEMICAL CO (JP) | 2024-04-24 | — | — | EP | disclosed |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2007025307-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070043023-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| WO-2007022459-A2 | PROCESSES AND INTERMEDIATES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007016589-A2 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2006127588-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006105035-A2 | MUSCARINIC MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-0799188-B1 | AMIDES OF MONO AND DICARBOXYLIC ACIDS WITH GLYCOSAMINES, SELECTIVELY ACTIVE ON THE CANNABINOID PERIPHERAL RECEPTOR | LIFEGROUP SPA (IT) | 1999-09-15 | — | — | EP | disclosed |
| EP-0799188-A2 | AMIDES OF MONO AND BICARBOXYLIC ACIDS WITH AMINO ACIDS OR GLYCOSAMINES, SELECTIVELY ACTIVE ON THE CANNABINOID PERIPHERAL RECEPTOR | LIFEGROUP S.p.A. (IT) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996018600-A1 | AMIDES OF MONO AND BICARBOXYLIC ACIDS WITH AMINO ACIDS OR GLYCOSAMINES, SELECTIVELY ACTIVE ON THE CANNABINOID PERIPHERAL RECEPTOR | LIFEGROUP S.P.A. (IT) | 1996-06-20 | — | — | WO | disclosed |
| JP-H07149825-A | POLYMER AND COPOLYMER OF DIENE, TERMINATED WITH COMPOUND HAVING MULTIPLE-BONDED NITROGEN ATOM AND PARTIALLY CROSS-LINKED WITH MULTIFUNCTIONAL CHEMICAL AGENT | BRIDGESTONE CORP | 1995-06-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | TSHR 2748/4885ALDH1A1 1961/4885 |
| US-20240124475-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | TSHR 4040/4885ALDH1A1 4160/4885 |
| US-20070043023-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | TSHR 131/4885ALDH1A1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.